title: Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs.
abstract: OBJECTIVE
  To evaluate the efficacy, overall esthetic effect, and safety of a new permanent, polyalkylimide dermal filler in HIV-infected patients with severe facial lipodystrophy.
  
  
  METHODS
  Eleven subjects with severe facial lipodystrophy secondary to HIV infection were injected bilaterally with 15 and 30 cm3 of a polyalkylimide gel into the buccal, malar, and temporal areas of the face in an attempt to restore their facial contour. The youngest treated subject was 31 years of age and the oldest 73 years of age.
  
  
  RESULTS
  All 11 subjects received an immediately acceptable therapeutic esthetic effect. Injections were generally well tolerated, with only three adverse events (swelling and bruising) recorded. Subjects, assessed at 3 and 18 months after treatment, continued to show improvement.
  
  
  CONCLUSIONS
  The immediate benefits of a polyalkylimide gel in the correction and restoration of facial contour in subjects having severe HIV-related facial lipodystrophy were demonstrated. This improvement was still noted at 18 months. The efficacy, ease of injection, and safety profile of polyalkylimide gel make this filling material a potentially attractive treatment for lipodystrophy. These data must be tempered with the need for significant further safety studies to determine whether this long-term filler has a safety profile consistent with other currently popular fillers.
authors.affiliation: Department of Medical Aesthetics, Ailesbury Clinic, Dublin, Ireland.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Treacy
authors.forename: David J
authors.initials: DJ
authors.lastname: Goldberg
mesh_terms: D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001704:Biopolymers / Q000008:administration & dosage; D003357:Cosmetic Techniques; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000032:analysis*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage*; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D001704:Biopolymers; D015483:HIV Antibodies; D008567:Membranes, Artificial; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide)